Treatment of relapsers after combination therapy for chronic hepatitis C

Infectious Disease Clinics of North America

Volumn 20, Issue 1, 2006, Pages 137-153

  Ahmed, Furqaan ^a   Jacobson, Ira M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ENZYME INHIBITOR; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; VIRUS ENZYME; VIRUS RNA;

ANEMIA; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; ETHNOLOGY; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; META ANALYSIS; NEUTROPENIA; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PREDICTION; RELAPSE; RETREATMENT; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS GENOME; VIRUS LOAD;

EID: 33644765750     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2006.01.010     Document Type: Review

References (57)

1. T. Poynard, P. Marcellin, S.S. Lee, C. Niederau, G.S. Minuk, and G. Ideo Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1998 1426 1432
2. J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, and V.K. Rustgi Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med 339 1998 1485 1492
3. J.Y.N. Lau, R.C. Tam, T.J. Liang, and Z. Hong Mechanisms of action of ribavirin in the combination treatment of chronic HCV infection Hepatology 35 5 2002 1002 1009
4. J.D. Graci, and C.E. Cameron Quasispecies, error catastrophe, and the antiviral activity of ribavirin Virology 298 2002 175 180
5. N.M. Dixit, J.E. Layden-Almer, and T.J. Layden Modelling how ribavirin improves interferon response rates in hepatitis C virus infection Nature 432 2004 922 924
6. G. Dusheiko, J. Main, H. Thomas, O. Reichard, C. Lee, and A. Dhillon Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study J Hepatol 25 1996 591 598
7. A.M. Di Bisceglie, M. Shindo, T.L. Fong, M.W. Fried, M.G. Swain, and N.V. Bergasa A pilot study of ribavirin therapy for chronic hepatitis C Hepatology 16 1992 649 654
8. H.C. Bodenheimer Jr., K.L. Lindsay, G.L. Davis, J.H. Lewis, S.N. Thung, and L.B. Seef Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multi-center trial Hepatology 26 1997 473 477
9. J.T. Brouwer, F. Nevens, and F.C. Bekkering Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients J Hepatol 40 2004 689 695
10. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
11. M.W. Fried, M.L. Shiffman, R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 13 2002 975 982
12. T. Poynard, J. McHutchison, and M. Manns Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313
13. S.A. Coverdale, M.H. Khan, and K. Byth Effects of interferon treatment response in liver complications of chronic hepatitis C: 9-year follow-up study Am J Gastroenterol 99 4 2004 636 644
14. G.L. Davis, and J.Y.N. Lau Factors predictive of a beneficial response to therapy of hepatitis C Hepatology 26 3 1997 S122 S127
15. V. Leroy, M. Baud, C. de Traversay, M. Maynard-Muet, P. Lebon, and J.P. Zarski Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C J Hepatol 28 3 1998 375 381
16. R.M. Hoffmann, T. Berg, G. Teuber, O. Prummer, L. Leifeld, and M.C. Jung Interferon antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis Z Gastroenterol 37 8 1999 715 723
17. A.U. Neumann, N.P. Lam, H. Dahari, D.R. Gretch, T.E. Wiley, and T.J. Layden Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy Science 282 1998 103 107
18. C. Sarrazin, G. Teuber, and R. Kokka Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays Hepatology 32 2000 818 823
19. W.C. Chow, N. Boyer, M. Pouteau, C. Castelnau, M. Martinot-Peignoux, and V. Martins-Amado Re-treatment with interferon alfa of patients with chronic hepatitis C Hepatology 27 1998 1144 1148
20. G.L. Davis, R. Esteban-Mur, V. Rustgi, J. Hoefs, S.C. Gordon, and C. Trepo Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C N Engl J Med 339 1998 1493 1499
21. O. Weiland, Y.Y. Zhang, and A. Widell Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment Scand J Infect Dis 25 1993 25 30
22. A. Picciotto, R. Brizzolara, N. Campo, G. Poggi, N. Sinelli, and V. De Conca Two-year interferon retreatment may induce a sustained response in relapsing patients with chronic hepatitis C Hepatology 24 4 1996 273A
23. J.L. Payen, J. Izopet, V. Galindo-Migeot, V. Lauwers-Cances, J.P. Zarski, and J.M. Seigneurin Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multi-center, controlled, randomized trial Hepatology 28 1998 1680 1686
24. H. Bell, K. Hellum, S. Harthug, B. Myrvang, S. Ritland, and A. Maeland Treatment with interferon-alpha 2a alone or interferon-alpha 2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha 2a Scand J Gastroenterol 34 1999 194 198
25. G. Barbaro, G. Di Lorenzo, G. Belloni, L. Ferrari, A. Paiano, and P. Del Poggio Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial Am J Med 107 1999 112 118
26. L. Cavalletto, L. Chemello, C. Donada, P. Casarin, F. Belussi, and E. Bernardinello The pattern of response to interferon alpha (α-IFN) predicts sustained response to a 6-month α-IFN and ribavirin retreatment for chronic hepatitis C J Hepatol 33 2000 128 134
27. J. Enriquez, A. Gallego, X. Torras, T. Perez-Olmeda, M. Diago, and V. Soriano Retreatment for 24 vs 48 weeks with interferon-α2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone J Viral Hepat 7 2000 403 408
28. R. Cozzolongo, R. Cuppone, V. Giannuzzi, L. Amati, L. Caradonna, and V. Tamborrino Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon Alimentary Pharmacology and Therapeutics 15 2001 129 135
29. G. Saracco, A. Olivero, A. Ciancio, S. Carenzi, A. Smedile, and G. Cariti A randomized 4-arm multi-center study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy Hepatology 36 2002 959 966
30. M.L. Shiffman, C.M. Hoofmann, R.K. Sterling, V.A. Luketic, M.J. Contos, and A.J. Sanyal A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response J Infect Dis 184 2001 405 409
31. 2b interferon plus ribavirin for 6 to 12 months J Hepatol 33 2000 456 462
32. A.D. Min, J.L. Jones, S. Esposito, E. Lebovics, I.M. Jacobson, and F.M. Klion Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone Am J Gastroenterol 96 4 2001 1143 1149
33. I. Portal, M. Bourliere, and P. Halfon Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study J Viral Hepatitis 10 2003 215 223
34. E.L. Krawitt, T. Ashikaga, and S.R. Gordon Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C J Hepatol 43 2005 243 249
35. I.M. Jacobson, S.A. Gonzalez, and F. Ahmed A randomized trial of pegylated interferon α-2b plus ribavirin in the retreatment of chronic hepatitis C Am J Gastroenterol 100 2005 1 10
36. P. Gaglio, J. Choi, and D. Zimmerman Weight based ribavirin in combination with pegylated interferon alpha 2-b does not improve SVR in HCV infected patients who failed prior therapy: results in 454 patients Hepatology 42 4, suppl 1 2005 219A
37. T. Poynard, E. Schiff, and R. Terg Sustained virologic response (SVR) with PEG-interferon-alfa-2b/ribavirin weight based dosing in previous interferon/ribavirin HCV treatment failures; week 12 virology as a predictor of SVR in the EPIC3 trials Gastroenterology 128 2005 A681
38. I. Portal, D. Botta-Fridlund, M. Bourliere, P. Couzigou, K. Barange, and V. Canva Treatment with pegylated-interferon alpha-2b (peg-interferon) + ribavirin in relapsers to standard interferon + ribavirin in chronic hepatitis C: efficacy and safety results from a randomized multi-centric French study Hepatology 36 4 2002 359A
39. E.J. Lawitz, N.S. Bala, S. Becker, G. Brown, M. Davis, and R. Dhar Pegylated interferon alfa 2b and ribavirin for hepatitis C patients who were nonresponders to previous therapy Gastroenterology 124 4 2003 A783
40. P. Ferenci Predictors of response to therapy for chronic hepatitis C Seminars in Liver Disease 24 Suppl 2 2004 25 31
41. G.L. Davis, J.B. Wong, J.G. McHutchison, M.P. Mann, J. Harvey, and J. Albrecht Early virologic response to treatment with pegylated interferon α-2b and ribavirin in patients with chronic hepatitis C Hepatology 38 2003 645 652
42. J.G. McHutchison, M. Manns, K. Patel, T. Poynard, K.L. Lindsay, and C. Trepo Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C Gastroenterology 123 2002 1061 1069
43. S.K. Herrine, R.S. Brown, and D.E. Bernstein Peginterferon α-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon α-2b plus ribavirin: a pilot study of efficacy and safety Dig Dis Sci 50 4 2005 719 726
44. C.J. Weegink, R.E. Sentjens, and M.G. Beld Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-α in combination with ribavirin and amantadine: a two-arm randomized pilot study J Viral Hepatol 10 2003 174 182
45. B. Freilich, A. Weston, L.J. DeGuzmann, and J. Kissinger Triple therapy for interferon/ribavirin failure patients with hepatitis C: interim data Hepatology 36 4 2002 361A
46. I.M. Jacobson, R.S. Brown, and B. Freilich Weight-based ribavirin dosing (WBD) increases sustained viral response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN-R study, a US community based trial Hepatology 42 4, Suppl 1 2005 749A
47. G.L. Davis, J.B. Wong, and J.G. McHutchison Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 2003 645 652
48. N.H. Afdhal, D.T. Dieterich, and P.J. Pockros Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study Gastroenterology 126 2004 1302 1311
49. F. Goncales, D.E. Berstein, C. Berg, H. Sette, J. Rasenack, and M. Diago Peginterferon alfa-2a (40KD) (Pegasys) plus ribavirin in chronic hepatitis C: retreatment of patients who relapsed virologically after 24 weeks of therapy Hepatology 36 4 2002 361A
50. M. Buti, A. Valdes, F. Sanchez-Avila, R. Esteban, and Y. Lurie Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases Hepatology 37 5 2003 1226 1227
51. C.B. Leevey, C.P. Chalmers, and L.M. Blatt Comparison of African American and Non-African American patient end of treatment response for Peg-IFN α-2 and weight-based ribavirin nonresponders re-treated with IFN alfacon-1 and weight-based ribavirin Hepatology 40 4, Suppl 1 2004 240A
52. S. Kaiser, H. Hass, and Gregor Successful retreatment of chronic hepatitis C patients with a nonresponse to standard interferon/ribavirin using daily consensus interferon and ribavirin Hepatology 40 4, Suppl 1 2004 240A
53. A.M. Di Bisceglie, J.G. McHutchison, and C.M. Rice New therapeutic strategies for hepatitis C Hepatology 35 1 2002 224 231
54. S. Zeuzem, C. Sarrazin, R. Rouzier, A. Tarral, N. Brion, and N. Forestier Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN-α) Hepatology 42 4, Suppl 1 2005 233A 234A
55. H.W. Reesink, S. Zeuzem, C.J. Weegink, N. Forestier, A. van VLiet, and J. ven de Wetering de Rooij Final results of a phase 1B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor Hepatology 42 4, Suppl 1 2005 234A 235A
56. C. O'Brien, E. Godofsky, M. Rodriguez-Torres, N. Afdhal, S.C. Pappas, and P. Pockros Randomized trial of valopicitabine (NM283), alone or in with PEG-interferon, vs. retreatment with PEG-interferon plus ribavirin (PEGIFN/RBV) in hepatitis C patients with previous nonresponse to PEGIFN/RBV: first interim results Hepatology 42 4, Suppl 1 2005 234A
57. R.T. Sarisky Non-nucleoside inhibitors of the HCV polymerase Journal of Antimicrobial Chemotherapy 54 2004 14 16